^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    REGN5093-M114

    i
    Other names: REGN5093-M114
    Company:
    Regeneron
    Drug class:
    Tubulin inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    2ms
    Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer (clinicaltrials.gov)
    P1/2, N=237, Recruiting, Regeneron Pharmaceuticals | N=83 --> 237 | Trial completion date: Dec 2026 --> Feb 2030 | Trial primary completion date: Dec 2026 --> Feb 2030
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MET overexpression
    |
    Libtayo (cemiplimab-rwlc) • REGN5093-M114
    10ms
    A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC (IASLC-WCLC 2023)
    Currently, this study is enrolling patients. As of 30 March 2023 17 patients across the five dose levels (table 1).Dose Level (DL)Number of patients enrolledDL11DL23DL33DL44DL56
    Clinical • P1/2 data
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression
    |
    REGN5093-M114
    over1year
    Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. (PubMed, Clin Cancer Res)
    Altogether, REGN5093-M114 is a promising candidate to overcome the challenges facing functional MET pathway blockade.
    Preclinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • PTEN (Phosphatase and tensin homolog)
    |
    EGFR mutation • MET amplification • EGFR overexpression • MET overexpression • MET mutation • MET expression • MET Y1230C
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • REGN5093-M114
    2years
    A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations (AACR 2022)
    We evaluated the antitumor activity of REGN5093-M114 in patient-derived tumor xenograft (PDX) models from EGFR-mutant NSCLC patients with acquired resistance to osimertinib plus savolitinib, including acquired MET p.Y1230C mutation. Finally, we determined whether REGN5093-M114 is able to overcome acquired resistance to the MET-TKI, tepotinib, using PDC from METex14 mutant NSCLC patients. In acquired MET-amplified EGFR-TKI resistant PDCs, PDOs, ATCC cell lines and PDX models, REGN5093-M114 alone exhibited a significant antitumor efficacy compared to MET-TKI or the MET x MET biparatopic antibody (REGN5093), but had no effect on some models with same MET copy number as the sensitive models... REGN5093-M114 has the potential to be a novel therapeutic option in NSCLC harboring MET genetic alterations, and further clinical application is highly warranted.
    Clinical • Late-breaking abstract
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase) • PTEN (Phosphatase and tensin homolog)
    |
    EGFR mutation • MET amplification • EGFR overexpression • MET exon 14 mutation • MET overexpression • MET mutation • MET expression • MET Y1230C
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib) • Tepmetko (tepotinib) • REGN5093-M114